Wonil Kim

Wonil Kim, Ph.D., is Chief Scientific Officer at Aston Sci., Inc., where he leads the development of next-generation mRNA-based cancer vaccines using the proprietary AI-driven Th-Vac® platform. His work focuses on designing immunotherapies that activate robust CD4+ T cell responses through MHC class II-restricted epitopes, enabling effective and durable anti-tumor immunity. He is currently advancing multiple pipeline programs, including mRNA vaccine candidates targeting shared tumor antigens and neoantigens.
Dr. Kim has over 20 years of experience in oncology research, immunology, and drug development. He earned his Ph.D. from the University of Minnesota and completed postdoctoral training at Harvard Medical School and the Frederick National Laboratory for Cancer Research (NIH). He previously served as a Staff Scientist at St. Jude Children’s Research Hospital and held leadership roles at GeneOne Life Science and Cyrus Therapeutics. His expertise spans nucleotide-based therapeutics, translational research, and strategic R&D leadership in the biopharmaceutical industry.